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Abstract
Background:  Legionella species cause severe forms of pneumonia with high mortality and
complication rates. Accurate clinical predictors to assess the likelihood of Legionella community-
acquired pneumonia (CAP) in patients presenting to the emergency department are lacking.
Methods: We retrospectively compared clinical and laboratory data of 82 consecutive patients
with Legionella CAP with 368 consecutive patients with non-Legionella CAP included in two studies
at the same institution.
Results: In multivariate logistic regression analysis we identified six parameters, namely high body
temperature (OR 1.67, p < 0.0001), absence of sputum production (OR 3.67, p < 0.0001), low
serum sodium concentrations (OR 0.89, p = 0.011), high levels of lactate dehydrogenase (OR 1.003,
p = 0.007) and C-reactive protein (OR 1.006, p < 0.0001) and low platelet counts (OR 0.991, p <
0.0001), as independent predictors of Legionella CAP. Using optimal cut off values of these six
parameters, we calculated a diagnostic score for Legionella CAP. The median score was significantly
higher in Legionella CAP as compared to patients without Legionella (4 (IQR 3–4) vs 2 (IQR 1–2), p
< 0.0001) with a respective odds ratio of 3.34 (95%CI 2.57–4.33, p < 0.0001). Receiver operating
characteristics showed a high diagnostic accuracy of this diagnostic score (AUC 0.86 (95%CI 0.81–
0.90), which was better as compared to each parameter alone. Of the 191 patients (42%) with a
score of 0 or 1 point, only 3% had Legionella pneumonia. Conversely, of the 73 patients (16%) with
≥4 points, 66% of patients had Legionella CAP.
Conclusion:  Six clinical and laboratory parameters embedded in a simple diagnostic score
accurately identified patients with Legionella CAP. If validated in future studies, this score might aid
in the management of suspected Legionella CAP.
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Background
Legionella species (spp.) causes a severe form of commu-
nity-acquired pneumonia (CAP) with a high incidence of
adverse medical outcomes including progression of infil-
trates, respiratory failure and need for intensive care unit
(ICU) admission [1,2]. In addition, Legionella CAP has a
high mortality rate of about 10 percent, which may
increase up to 27 percent in patients not receiving ade-
quate antibiotics as part of the empiric treatment on
admission [2]. Early identification of Legionella  spp. in
patients presenting with respiratory symptoms and suspi-
cion of CAP to the emergency department is thus of
utmost importance because it affects the timing and
choice of empirical antibiotic therapy and reduces the risk
for adverse outcome. Currently available diagnostic tests
include detection of Legionella spp. by culture or polymer-
ase chain-reaction (PCR) in respiratory samples and
Legionella pneumophila antigen testing in urine. These tests
lack sensitivity, in addition the urine antigen test only
identifies Legionella pneumophila serogroup 1 [3,4]. Previ-
ous studies comparing clinical, radiological and labora-
tory findings in Legionella CAP and non-Legionella CAP
have produced controversial results [1,5-12]. Two previ-
ous attempts to construct a diagnostic score that identifies
Legionella in patients with CAP have been disappointing
[1,5-11]. As a limitation, these studies compared
Legionella pneumophila CAP with selected cases of pneu-
mococcal CAP [5,6,8]. When applied in unselected
patients, these scores lack sensitivity and/or specificity.
Because of this diagnostic dilemma consensus guidelines
on empiric antibiotic therapy for patients with CAP to
extend antibiotic coverage to Legionella in all patients with
severe CAP contributing to antibiotic overuse and emer-
gence of multi-resistant strains [13-16]. However more
recent findings suggest, that severity of CAP is not an
appropriate screening criterion for Legionella CAP, which
further complicates the choice of empiric antibiotic treat-
ment [4].
The aim of this study was to compare initial clinical and
laboratory parameters of consecutive patients with
Legionella CAP who were hospitalized in our institution
during the last 10 years with patients with non-Legionella
CAP included in two studies at the same institution
[17,18] and thereby to identify reliable diagnostic predic-
tors of Legionella CAP.
Methods
Setting and Study population
We retrospectively evaluated all consecutive patients who
were admitted to the University Hospital in Basel, Switzer-
land from 1997 to 2007, with a diagnosis of Legionella
CAP. The diagnosis of Legionella was considered definite if
Legionella was either isolated by culture or PCR of a respi-
ratory sample or detected by urinary antigen testing.
Patient records were reviewed with a standardized data-
collection form to retrieve all demographic, clinical,
microbiological, radiographic, laboratory and therapeuti-
cal data. To achieve a reasonable comparison, we used
clinical and laboratory data on admission to the emer-
gency department.
For comparison we used data on admission of a consecu-
tive cohort of 368 patients with non-Legionella CAP who
were admitted between December 2002 through February
2005 to the same institution and enrolled in two studies
[17,18]. The design of the two studies was similar and has
been reported in detail elsewhere [17,18]. In brief, a total
of 373 consecutive patients with radiologically proven
CAP were randomly assigned to be treated either with a
procalcitonin (PCT)-based algorithm or standard practice.
The primary endpoint of the two studies was to evaluate
antibiotic exposure of a PCT-guided treatment algorithm
as compared to standard recommended guidelines [14].
Both studies excluded patients with cystic fibrosis or active
pulmonary tuberculosis, hospital-acquired pneumonia
and severely immunocompromized patients. In both
studies, testing for Legionella with the use of the urine anti-
gen test was recommended in all CAP patients as part of
the hospital work up for CAP and part of the study proto-
cols. Investigation for other atypical bacterial pathogens
namely Mycoplasma spp. and Chlamydia spp. were only
tested in suspected cases upon the decision of to the treat-
ing physicians. For the purpose of this study, the five
enrolled patients with Legionella CAP were analyzed in the
Legionella CAP group.
The two intervention studies were previously approved by
the local Ethical Committee (EKBB, Ethikkommission
beider Basel) and registered in the current controlled trials
databases. The Institutional Review Board classified this
retrospective analysis as a quality control study and
waived the need for informed consent.
CAP was defined as the presence of an infiltrate on chest
radiograph and at least one of the following signs and
symptoms (cough, sputum production, dyspnea, core
body temperature >38.0°C, auscultatory findings of
abnormal breath sounds and rales [19]. In all patients the
Pneumonia Severity Index (PSI) and the CURB65 were
calculated based on patients unique set of variables as
described in detail elsewhere [20,21]. The goldstandard
for diagnosis of Legionella CAP was the clinical diagnosis
of a community-acquired pneumonia with an infiltrate
on chest X-ray and at least one positive microbiological
test for Legionella (urinary antigen testing, culture results
from respiratory specimen or PCR from respiratory speci-
men).BMC Pulmonary Medicine 2009, 9:4 http://www.biomedcentral.com/1471-2466/9/4
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Laboratory assessment
For our analysis, we used laboratory results including
markers of infection (white blood count (WBC) and C-
reactive protein (CRP)), liver enzymes (ALAT, ASAT, γ-
glutamyltranspeptidase, alkaline phosphatase, bilirubin),
markers of renal function (creatinine, urea), electrolytes
(sodium, potassium), urinary testing for proteinuria and
hemoglobinuria and results from arterial blood gas anal-
ysis (pH, PaO2) from the routinely collected blood anal-
ysis of all patients on admission. In our hospital, CRP
concentrations are determined by an enzyme immu-
noassay having a detection limit of <5 mg/dl (EMIT,
Merck Diagnostica, Zurich, Switzerland).
In the group of Legionella CAP Legionella spp. was diag-
nosed either by antigen in urine detection (Legionella
pneumophila  serogroup 1) using an immunoenzymetric
commercial method (Legionella Urinary Antigen; Binax),
by PCR from respiratory samples using an in-house PCR
technique from the Institute for Medical Microbiology
(IMM) in Zurich, Switzerland, or by culture [22,23].
Statistical analysis
Discrete variables are expressed as counts (percentage)
and continuous variables as medians and interquartile
ranges (IQR). Frequency comparison was done by chi-
square test. Two-group comparison of normally distrib-
uted data was performed by Students t-test. For data not
normally distributed, the Mann-Whitney-U test was used.
To estimate the potential clinical relevance of laboratory
and clinical parameters to diagnose Legionella CAP, we
used likelihood-ratio tests and univariate and multivariate
logistic regression models. Thereby, outcomes were either
Legionella CAP or non-Legionella CAP. For all independent
variables in multivariate analysis, we calculated receiver-
operating-characteristics (ROC) with the area under the
ROC curve (AUC) being an overall diagnostic measure.
For all calculations we used STATA 9.2 statistical software
(Stata Corp, College Station, Tex). All testing was two-
tailed and P-values less than 0.05 were considered to indi-
cate statistical significance.
Results
Baseline parameters
This pooled analysis includes 82 patients with the definite
diagnosis of Legionella CAP and 368 patients with non-
Legionella CAP. The median age of the pooled 450 patients
was 72 years (IQR 58–81) and 62% were males. Patients
with Legionella CAP were significantly younger (68 (IQR
49–77) vs 73 (IQR 59–82), p = 0.01), and had less fre-
quent underlying chronic obstructive pulmonary disease
(10% vs 24%, p = 0.004) and heart disease (24% vs 42%,
p = 0.003). Cough (70% vs 89%, p < 0.001), increase in
sputum production (34% vs 72%, p < 0.001) and dyspnea
(60% vs 72%, p < 0.03), the cardinal symptoms of CAP,
were more frequently found in non-Legionella CAP, while
Legionella CAP patients had a higher median body temper-
ature on presentation (39.3°C vs. 38.4°C, p < 0.001). As
demonstrated in Table 1, Legionella  CAP patients had
higher concentrations of CRP, lactate dehydrogenase
(LDH) and creatinine kinase (CK), more frequently ele-
vated liver enzymes, proteinuria and hemoglobinuria and
lower concentrations of sodium, platelets and pH as com-
pared to non-Legionella CAP patients. Additional demo-
graphic, clinical and laboratory data are presented in
Table 1. Cough, increase of sputum production, dyspnea
and confusion in patients with Legionella CAP were avail-
able in 96% (n = 79), 94% (n = 77), 94% (n = 77) and
96% (n = 79), respectively.
The diagnosis of the 82 patients with Legionella CAP was
established with a total of 164 microbiological tests
including 72 urinary antigen tests, 54 cultures and 38
PCRs of respiratory specimen. Because in most patients
multiple diagnostic tests were performed, addition did
not sum up to 100%. As demonstrated in Table 2, three
different etiologic groups of Legionella  were identified,
namely 69.5% (n = 59) with only Legionella pneumophila
serogroup 1, 15.9% (n = 13) with Legionella pneumophila
and  Legionella  species and 14.6% (n = 12) with only
Legionella species, whereas in the previous two groups (n
= 13 and n= 12) serogroups and species of Legionella were
not otherwise specified. Among patients who received uri-
nary antigen testing, results for Legionella pneumophila
serogroup 1 were positive in 59 of 72 patients (82%). In
patients with negative urinary antigen testing (n = 13),
diagnosis of Legionella  was established by culture in 5
patients and/or PCR in 13 patients. In patients with no
urine antigen testing (n = 10) diagnosis was ascertained by
culture and/or PCR. In the 368 patients with non-
Legionella CAP urinary antigen testing for Legionella pneu-
mophila serogroup 1 was performed with negative results.
In these patients a causative microorganism in blood was
found in 8.4% (Streptococcus pneumoniae (6.0%), Staphylo-
coccus aureus (0.8%),  Escherichia coli (0.4%),  Klebsiella
pneumoniae (0.2%) and others (1.0%)).
Diagnostic reliability of clinical and laboratory parameters
To assess the diagnostic reliability of laboratory parame-
ters and clinical signs to identify Legionella CAP patients,
we calculated univariate logistic regression analysis (Table
3) with all parameters that were significantly different
between  Legionella  and non-Legionella  CAP patients on
presentation. Further, to identify independent predictors
of Legionella, we calculated multivariate logistic regression
analysis (Table 3). Multivariate analysis identified two
clinical parameters, namely body temperature (OR 1.67, p
< 0.0001), and absence of sputum production (OR 3.67,
p < 0.0001), and four laboratory parameters, namely
sodium (OR 0.89, p = 0.01), LDH (OR 1.003, p = 0.007),BMC Pulmonary Medicine 2009, 9:4 http://www.biomedcentral.com/1471-2466/9/4
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CRP (OR 1.006, p < 0.0001) and platelet counts (OR
0.991, p < 0.0001) as independent predictors of Legionella
CAP, respectively. To estimate the clinical usefulness of
these parameters and to compare sensitivities and specifi-
cities, ROC curves using these 6 predictors were calculated
(Figure 1). The area under the ROC curve, optimal cut off
values and corresponding sensitivities and specificities are
presented in table 4 for each variable at the optimal cut off
point are presented in Table 4. Using these optimal cut off
values, we calculated a 6 point diagnostic score giving a
Table 1: Baseline Characteristics of the 450 Patients with CAP separated by Legionella CAP (n = 82) and non-Legionella CAP (n = 368).
Legionella CAP 
(n = 82)
Non-Legionella CAP 
(n = 368)
P-value
Demographic characteristics
- Age (years)* 68 (49–77) 73 (59–82) 0.01
- Sex (male) – no. (%) 57 (70) 221 (60) 0.11
Coexisting illnesses – no. (%)
- Congestive heart disease 20 (24) 156 (42) 0.003
- Cerebrovascular disease 7 (9) 20 (5) 0.29
- Renal dysfunction 23 (28) 100 (27) 0.15
- COPDa 8 (10) 90 (24) 0.004
- Neoplastic disease 17 (21) 53 (14) 0.15
Clinical History – no. (%)
- Antibiotic pretreatment 27 (33) 75 (20) 0.01
- Cough 55 (70) 329 (89) <0.001
- increase in sputum production 26 (34) 265 (72) <0.001
- Dyspnea 46 (60) 266 (72) 0.03
Clinical and laboratory findings
- Confusion – no. (%) 9 (11) 31 (8) 0.4
- Respiratory rate (breaths/minute)* 18 (16–28) 22 (20–28) 0.01
- Systolic blood pressure (mmHg)* 130 (113–145) 130 (113–143) 0.9
- Heart rate (beats/minute)* 100 (86–114) 95 (80–110) 0.05
- Body temperature (°C)* 39.3 (38.5–40.1) 38.4 (37.6–39.2) <0.001
Laboratory findings
- C-reactive protein (mg/L)* 241 (171–315) 134 (67–217) <0.001
- Procalcitonin (μg/L)* 2.90 (0.93–6.43) 0.57 (0.19–2.61) <0.01
- Hematocrit (%)* 37 (32–41) 38 (35–40) 0.17
- Leucocyte counts (×109/L)* 12.9 (9.5–15.5) 12.8 (8.9–16.8) 0.47
- Platelet counts (×109/L)* 191 (141–253) 243 (190–326) <0.001
- Sodium (mmol/L)* 132 (128–135) 136 (133–138) <0.001
< 131 mmol/L – no. (%) 36 (46) 49 (14) <0.001
- Creatinine (umol/L)* 101 (80–144) 105 (83–138) 0.29
- Urea (mmol/L)* 8.3 (5.4–14.2) 6.9 (4.9–11.5) 0.93
- Elevated liver enzymesb – no. (%) 52 (63) 126 (34) <0.001
- Creatinine kinase (U/L)* 103 (48–417) 77 (41–174) <0.01
- Lactate dehydrogenase (U/L)* 252 (204–382) 214 (175–268) <0.001
- Glucose (mmol/L)* 6.9 (6.1–9.7) 6.8 (5.9–8.4) 0.12
- Oxygen saturation (%)* 93 (88–95) 93 (89–96) 0.46
- PaO2 (kPa)* 7.7 (7.1–9.9) 8.0 (6.8–9.5) 0.82
- pH* 7.46 (7.38–7.49) 7.43 (7.39–7.46) 0.02
- Hemoglobinuria – no. (%) 45 (70) 114 (45) <0.001
- Proteinuria – no. (%) 46 (73) 124 (48) <0.001
Risk assessment
- PSIc Points* 117 (90–140) 95 (73–121) <0.001
- CURB65* 2 (1–2) 1 (1–2) 0.09
Outcome – no. (%)
- Death 13 (16) 33 (9) 0.06
- Admission to ICUd 34 (41) 43 (12) 0.01
- Length of hospital stay (days)* 13 (8–20) 11 (6–17) 0.02
* denotes median (interquartile range); a COPD denotes chronic obstructive pulmonary disease; b elevated liver enzymes denotes elevation of 
ASAT and/or ALAT; c PSI denotes Pneumonia Severity Index; d ICU denotes intensive care unit.BMC Pulmonary Medicine 2009, 9:4 http://www.biomedcentral.com/1471-2466/9/4
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point for each variable beyond the optimal cut off.
Patients with Legionella  CAP had a significantly higher
median score as compared to patients without Legionella
(4 (IQR 3–4) vs 2 (IQR 1–2), p < 0.0001). The odds ratio
of this score to predict Legionella was 3.34 (95%CI 2.57–
4.33, p < 0.0001). With an area under the curve (AUC) of
0.86 (95%CI 0.81–0.90), the diagnostic accuracy of this
diagnostic score was significantly better as compared to
each single one of the six parameters. Table 5 shows cor-
responding sensitivities, specificities and the number of
patients with and without Legionella CAP for each cut off
point of the diagnostic score. In Figure 2 the distribution
of  Legionella  and non-Legionella  CAP according to the
score is demonstrated. Of the 191 patients (42%) with 0
or 1 point, only 6 (3%) had Legionella pneumonia. Con-
versely, of the 73 patients (16%) with ≥4 points, 48
patients (66%) had Legionella CAP.
Discussion
The timely identification of Legionella in patients present-
ing with CAP to the emergency department is challenging
because single clinical and laboratory parameters have
shown low sensitivity and/or specificity. A reliable diag-
nostic score integrating different parameters is lacking [8].
The results of this study indicate that six clinical and lab-
oratory parameters, namely high body temperature,
absence of sputum production, low serum sodium and
platelet counts, and high LDH and CRP concentrations
combined in a diagnostic score reliably estimate the like-
lihood of Legionella in patients who present with CAP to
the emergency department.
Current guidelines on the management of patients with
CAP recommend that empirical antibiotic coverage
should be extended to Legionella  in "suspicious cases",
although no single parameter can reliably identify or rule
out patients at risk for Legionella [8,13]. Previous studies
have addressed this dilemma and assessed potential pre-
dictors of Legionella CAP in different settings [1,5-12]. A
Spanish study found that Legionella should be suspected
in middle-aged, alcohol drinking, healthy male patients,
Table 2: Results of microbiological tests (n = 164) in all patients with Legionella CAP (n = 82).
Established by \Etiologic Diagnosis L. pn 1a 
(n = 57)
L. pnb & L.
spp.c
(n = 13)
L. spp
(n = 12)
Urinary antigen testing (n = 72) Positive (n = 59) 50 9 0
Negative (n = 13) 1 4 8
Respiratory specimen
culture (n = 54)
Positive (n = 23) 14 8 1
Negative (n = 31) 19 5 7
Respiratory specimen
PCRd (n = 38)
Positive (n = 34) 10 13 11
Negative (n = 4) 4 0 0
a L. pn 1, b L. pn and c L. spp. denote Legionella pneumophila serogroup 1, Legionella pneumophila and Legionella species; d PCR denotes polymerase 
chain-reaction, respectively.
The goldstandard for diagnosis of Legionella CAP was the clinical diagnosis of a community-acquired pneumonia with an infiltrate on chest X-ray and 
at least one positive microbiological test for Legionella (urinary antigen testing, culture results from respiratory specimen or PCR from respiratory 
specimen).
Table 3: Prediction of Legionella CAP (n = 82) in univariate (a) 
and multivariate (b) logistic regression analysis
Univariate analysis
Predictor Odds ratio (95% CI*) P-value
Age 0.98 0.97 1.00 0.017
Temperature 1.93 1.51 2.46 <0.0001
No dyspnea 1.75 1.06 2.9 0.03
No cough 3.7 2.05 6.6 <0.0001
No sputum 5.14 3.04 8.7 <0.0001
Sodium 0.86 0.82 0.91 <0.0001
Elevated liver enzymes1 3.32 2.02 5.48 <0.0001
Lactate dehydrogenase 1.003 1.002 1.005 0.001
Creatinine kinase 1.001 1.000 1.001 0.001
C-reactive protein (CRP) 1.006 1.004 1.008 <0.0001
Platelet counts 0.993 0.990 0.996 <0.0001
Hemoglobinuria 2.95 1.64 5.32 <0.0001
Proteinuria 2.88 1.56 5.29 0.001
Multivariate analysis
Predictor Odds ratio (95% CI) P-value
Temperature 1.67 1.23 2.32 <0.0001
No sputum 3.67 1.8 7.4 <0.0001
Sodium 0.89 0.84 0.96 0.01
Lactate dehydrogenase 1.003 1.000 1.005 0.007
C-reactive protein (CRP) 1.006 1.003 1.009 <0.0001
Platelet counts 0.991 0.987 0.995 <0.0001
* Cl denotes confidence interval; 1 elevated liver enzymes denotes 
ASAT and/or ALAT.BMC Pulmonary Medicine 2009, 9:4 http://www.biomedcentral.com/1471-2466/9/4
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if patients lack response to previous beta-lactamic drugs,
if headache, diarrhea, severe hyponatremia, and elevation
in serum CK levels were present, or if no cough, expecto-
ration, and thoracic pain were found [12]. A recent critical
review included 13 different studies that reported clinical
details for the evaluation of Legionella CAP, however, con-
cluded that using a syndromic approach cannot be recom-
mended and, thus, an empiric antibiotic therapy covering
for Legionella for all patients with CAP requiring hospital-
ization should be recommended [8]. This, however,
results in indiscriminate use of, mostly unnecessary, dual
antibiotic therapy and thus, increased antibiotic exposure
and emergence of resistance. Two previous studies have
proposed a clinical prediction rule to identify Legionella
CAP [5,6]. The CBPIS score has been proposed with a
maximum of 17 points based on the evaluation of tem-
perature, serum creatinine, sodium and LDH concentra-
tions, headache, vomiting and smoking. However, in a
prospective validation study, this scoring system had a
low sensitivity and/or specificity to diagnose or exclude
Legionella CAP [5]. Guidance of antibiotic therapy using
this score would have left half of the patients with
Legionella CAP without specific coverage and would have
led to the administration of an unnecessarily broad anti-
biotic regimen in 14% of patients without Legionella. In
addition, the model was unable to distinguish between
Legionella pneumophila and  Streptococcus pneumoniae,
because the majority of patients were categorized into the
"intermediate-probability" group. Similarly, the clinical
criteria proposed by the Winthrop-University Hospital
(WUH) for the identification of Legionellosis showed an
inadequately low sensitivity and specificity of 78% [6]. In
addition, the WUH study included clinical data collected
throughout the first 7 days of hospitalization limiting its
use as a screening tool in an emergency department set-
ting. Importantly, both studies based their scoring system
on the comparison of Legionella CAP with pneumococcal
CAP, which does not reflect the clinical situation in the
emergency department, where the decision about empiri-
cal antibiotic therapy must be taken in all patients with
CAP. In this study, a thorough and comprehensive 10 year
retrospective data collection was conducted and data from
two prospective studies presenting to the emergency
department of the same institution were used to compare
clinical and laboratory parameters. Thus we believe the
proposed score reflects the clinical situation more realisti-
cally.
Simplicity of a diagnostic score is a major determinant for
its future usefulness in daily practice. The WUH scale con-
sists of 23 different criteria, which increases its complexity
and may correlate with non-adherence as observed in
clinical severity prediction scores [6,24]. The herein pro-
posed scoring system composes of only 6 routinely meas-
ured clinical and laboratory parameters that showed an
independent predictive value in multivariate logistic
regression analysis and a high overall diagnostic perform-
ance as demonstrated in ROC analysis.
As with any diagnostic score, the "optimal" cut off should
be chosen based on the pretest probability and the clinical
context, particularly the risk for adverse medical outcomes
Table 4: Area under the curve (AUC) of receiver operating curve (ROC) characteristic plot analysis.
Parameter AUC 95% CI* P-value Optimal cut off Sensitivity Specificity
Combined Score 0.86 0.81–0.90 - < 2 78.0 78.8
Temperature 0.74 0.63–0.78 <0.0001 > 39.4 48.1 84.4
No sputum 0.68 0.61–0.74 <0.0001 - - -
Sodium 0.71 0.63–0.78 <0.0001 < 133 64.6 70.8
Lactate dehydrogenase 0.62 0.53–0.71 <0.0001 > 225 67.1 58.1
C-reactive protein 0.76 0.70–0.82 <0.0001 > 187 71.6 64.7
Platelet counts 0.71 0.64–0.78 <0.0001 < 171 45.7 83.6
*CI denotes confidence interval;
Table 5: Diagnostic accuracy of the diagnostic score at different cut off points.
Points Sensitivity Specificity Legionella CAP Non-Legionella CAP
≥ 01 0 0 - 0 (0%) 70 (19.0%)
≥ 1 92.7 50.3 6 (7.3%) 115 (31.3%)
≥ 2 78.0 78.8 12 (14.6%) 105 (28.5%)
≥ 3 58.5 93.2 16 (19.5%) 53 (14.4%)
≥ 4 14.6 98.9 36 (43.9%) 21 (5.7%)
≥ 5 2.4 100 10 (12.2%) 4 (1.1%)
6 - 100 2 (2.4%) 0 (0%)BMC Pulmonary Medicine 2009, 9:4 http://www.biomedcentral.com/1471-2466/9/4
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of patients. Supported by recent guidelines, treatment
decision on the empirical antibiotic therapy should be
based on both, the diagnostic probability and the risk of
patients based on a prognostic assessment. Importantly,
the PSI – but not the CURB65 score – showed a high prog-
nostic accuracy to predict adverse medical outcomes in
patients with Legionella CAP in this study. This finding is
reassuring because prognostic CAP scores mainly depend
on age and Legionella CAP patients tend to be younger.
Thus, taking the diagnostic limitations of urinary antigen
testing into account, empirical antibiotic therapy covering
for atypical pathogens in patients with negative urinary
antigen testing but high diagnostic probability (diagnostic
score  ≥ 4) may be advisable. Conversely, in low risk
patients with low diagnostic probability (diagnostic score
≤ 1) and no clinical or diagnostic evidence of CAP caused
by other atypical pathogens, macrolides may initially be
withheld until the results of the urinary antigen tests
become available.
Some limitations should be considered in interpreting our
results. With a retrospective design, our results are prelim-
inary and prospective validation is needed prior to a wide-
spread use in clinical practice. The diagnosis of Legionella
spp. in non-Legionella CAP patients was performed rou-
tinely by urinary antigen testing without PCR, culture or
serology and we may have classified some patients incor-
rectly. Moreover there was no further routinely investiga-
tion for other atypical bacterial pathogens. We chose the
10 year retrospective design to provide the necessary
number of Legionella cases to calculate multivariate analy-
sis with adequate power. The proposed score consists of
Receiver Operating Curve (ROC) analysis of different clinical and laboratory parameters to differentiate Legionella CAP from  non-Legionella CAP Figure 1
Receiver Operating Curve (ROC) analysis of different clinical and laboratory parameters to differentiate 
Legionella CAP from non-Legionella CAP. AUC denotes area under the curve; LDH and CRP denote lactate dehydroge-
nase and C-reactive protein.
 BMC Pulmonary Medicine 2009, 9:4 http://www.biomedcentral.com/1471-2466/9/4
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mainly objectively measurable parameters, which may
robustly be ascertained in retrospect. Still, anamnestic
parameters (i.e. absence of sputum production), even if
highly available, may not be accurately assessed in retro-
spect and are thus underestimated in favour of laboratory
parameters and clinical data.
Conclusion
In conclusion, the results of this study suggest that six clin-
ical and laboratory signs embedded in a simple diagnostic
score allow better differentiation of Legionella from unse-
lected patients with non-Legionella CAP presenting to the
emergency department. If confirmed in prospective stud-
ies, this score might improve the timing and choice of
empirical antibiotic therapy and thus reduce the associ-
ated morbidity and mortality and the emergence of bacte-
rial resistance.
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